Industry: Pharmaceuticals (See others in industry)
Address:| Date | FilingType | Incremental Cash | Link to Raw Filing | |||
|---|---|---|---|---|---|---|
| 2025-01-15 | New | $175,000 | $175,000 | Equity Only | 06b | SEC link |
| 2024-12-12 | New | $2,000,000 | $2,000,000 | Equity Only | 06b | SEC link |
| 2024-12-12 | New | $498,000 | $498,000 | Equity Only | 06b | SEC link |
| 2022-02-18 | Amended | $2,011,300 | $1,530,175 | Equity Only | 06b | SEC link |
| 2021-01-07 | New | $481,125 | $481,125 | Equity Only | 06b | SEC link |
| Name | Role |
|---|---|
| John Scott Keadle | Director, Executive |
| Mark Sebree | Director |
| John Selig | Director |
| Atif Zia | Director |